AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2458686 — intervention group
Group type: COMPARATOR
Intervention: isoflurane anesthesia without narcotics
Number of subjects: 14
Study 2458686 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF substance P concentrations before the start of PCA
Number of subjects: 14
Study 2458686 — intervention group
Group type: EXPERIMENTAL
Intervention: individual changes in substance P concentrations during PCA
Number of subjects: 14
Study 2458686 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF (Met)enkephalin‐Arg6‐Phe7 concentrations
Number of subjects: 14
Study 2458686 — intervention group
Group type: EXPERIMENTAL
Intervention: interindividual variability in substance P and (Met)enkephalin‐Arg6‐Phe7 concentrations
Number of subjects: 14
Study 31676670 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (arm A)
Number of subjects: 113
Study 31676670 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (arm B)
Number of subjects: 113
Study 31676670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (arm C)
Number of subjects: 113
Study 31676670 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (arm D)
Number of subjects: 113
Study 31676670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-based IFNγ gene signature (arm E)
Number of subjects: 113
Study 29050009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab
Number of subjects: 208
Study 29050009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab
Number of subjects: 208
Study 29050009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Triamcinolone
Number of subjects: 208
Study 28098954 — intervention group
Group type: EXPERIMENTAL
Intervention: Play therapy
Number of subjects: 0
Study 26591681 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage treatment 1 and 2
Number of subjects: 180
Study 26591681 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment 1 and 2
Number of subjects: 180
Study 24134956 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized self-management support using the SeMaS questionnaire
Number of subjects: 15
Study 24134956 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 15
Study 20349353 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving cancer treatment
Number of subjects: 285
Study 20349353 — intervention group
Group type: COMPARATOR
Intervention: Patients awaiting new treatment
Number of subjects: 285
Study 20349353 — intervention group
Group type: COMPARATOR
Intervention: Patients on surveillance or whose treatment had been stopped
Number of subjects: 285
Study 19004162 — intervention group
Group type: COMPARATOR
Intervention: Weight-loss supplement
Number of subjects: 120
Study 19004162 — intervention group
Group type: COMPARATOR
Intervention: Telephone coaching
Number of subjects: 120
Study 19004162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplement and coaching
Number of subjects: 120
Study 16990155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise and diet counselling)
Number of subjects: 151
Study 16990155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 151
Study 13130145 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID therapy
Number of subjects: 639
Study 13130145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study 12212248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume ventilation (tidal volume 6-8 ml.kg-1)
Number of subjects: 35
Study 12212248 — intervention group
Group type: COMPARATOR
Intervention: Normal volume ventilation (tidal volume 12-14 ml.kg-1)
Number of subjects: 35
Study 8941026 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (300 mg) administered orally and intravenously
Number of subjects: 16
Study 8941026 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (300 mg) administered orally 4 hours before hemodialysis
Number of subjects: 16
Study 14621771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 10 mg/kg per day
Number of subjects: 49
Study 14621771 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 49
Study 14621771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 49
Study 3932470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusions
Number of subjects: 24
Study 3932470 — intervention group
Group type: COMPARATOR
Intervention: Exercise (control)
Number of subjects: 24
Study 3932470 — intervention group
Group type: COMPARATOR
Intervention: Saline infusions (control)
Number of subjects: 24
Study 31422740 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Controlled Knowledge of Results (SC KR)
Number of subjects: 24
Study 31422740 — intervention group
Group type: COMPARATOR
Intervention: Yoked Control Group
Number of subjects: 24
Study 29859570 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential Interaural Intensity Difference (DIID) training
Number of subjects: 12
Study 29859570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic Offset Training (DOT)
Number of subjects: 12
Study 27062041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (250 mg)
Number of subjects: 9
Study 27062041 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia without vitamin E supplementation
Number of subjects: 9
Study 24577880 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy (PDT)
Number of subjects: 47
Study 24577880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 47
Study 24577880 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 47
Study 22812731 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airways pressure treatment for patients with obstructive sleep-disordered breathing (apnea hypopnea index ≥20)
Number of subjects: 200
Study 22812731 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airways pressure treatment
Number of subjects: 200
Study 22812731 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of vascular functions and markers (blood pressure, heart rate variability, endothelial function, specific humoral factors)
Number of subjects: 200
Study 19266407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding social capital (treatment and emotional buddy)
Number of subjects: 268
Study 19266407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging social capital (community health worker and support group)
Number of subjects: 268
Study 19266407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding and bridging social capital
Number of subjects: 268
Study 17585003 — intervention group
Group type: EXPERIMENTAL
Intervention: NAAGA eye-drops
Number of subjects: 23
Study 17585003 — intervention group
Group type: COMPARATOR
Intervention: LEVO eye-drops
Number of subjects: 23
Study 16114155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclogest (n=35)
Number of subjects: 161
Study 16114155 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone gel (n=36)
Number of subjects: 161
Study 16114155 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrogestan (n=55)
Number of subjects: 161
Study 16114155 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG (n=35)
Number of subjects: 161
Study 11799502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (group R2, n = 19)
Number of subjects: 58
Study 11799502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (group R1, n = 19)
Number of subjects: 58
Study 11799502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine with 2 microg/mL fentanyl (group RF, n = 20)
Number of subjects: 58
Study 10512907 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 17
Study 10512907 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 17
Study 7992988 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 65000
Study 7992988 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 65000
Study 7992988 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blockers
Number of subjects: 65000
Study 7992988 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors
Number of subjects: 65000
Study 7992988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 65000
Study 1941733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms twice daily for 12 weeks
Number of subjects: 25
Study 1941733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6785791 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 6785791 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 6785791 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 6785791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31833452 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based information tool and nurse delivered telephone support
Number of subjects: 75
Study 31833452 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 30655568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily for 2 weeks
Number of subjects: 40
Study 30655568 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 28407735 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine treatment starting at 12 weeks (Group A; n=62)
Number of subjects: 188
Study 28407735 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine treatment starting at 20-28 weeks (Group B; n=61)
Number of subjects: 188
Study 28407735 — intervention group
Group type: COMPARATOR
Intervention: No antiviral treatment (Group C; n=65)
Number of subjects: 188
Study 27697880 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 0
Study 27697880 — intervention group
Group type: COMPARATOR
Intervention: Education + Feedback
Number of subjects: 0
Study 27697880 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 0
Study 24369433 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma reduction intervention in healthcare settings
Number of subjects: 217
Study 24369433 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 217
Study 22499579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator
Number of subjects: 62
Study 22499579 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic approach to mismatch definition
Number of subjects: 62
Study 19852303 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilong Tongluo Capsule (GTC) combined with prednisone
Number of subjects: 60
Study 19852303 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 60
Study 17052823 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 205
Study 17052823 — intervention group
Group type: EXPERIMENTAL
Intervention: Care interventions including acupuncture
Number of subjects: 205
Study 17052823 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture group
Number of subjects: 205
Study 17052823 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 205
Study 17052823 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Group B streptococci in breast milk
Number of subjects: 205
Study 15102339 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1200 mg
Number of subjects: 61
Study 15102339 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (Celebrex) 200 mg
Number of subjects: 61
Study 15102339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SAMe and celecoxib
Number of subjects: 61
Study 12054376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray lens tint
Number of subjects: 25
Study 12054376 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown lens tint
Number of subjects: 25
Study 12054376 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow lens tint
Number of subjects: 25
Study 12054376 — intervention group
Group type: EXPERIMENTAL
Intervention: Green lens tint
Number of subjects: 25
Study 12054376 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple lens tint
Number of subjects: 25
Study 12054376 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue lens tint
Number of subjects: 25
Study 12054376 — intervention group
Group type: COMPARATOR
Intervention: Clear lens
Number of subjects: 25
Study 9665109 — intervention group
Group type: EXPERIMENTAL
Intervention: whole-protein-based formula (n = 22)
Number of subjects: 49
Study 9665109 — intervention group
Group type: EXPERIMENTAL
Intervention: peptide-based formula (n = 17)
Number of subjects: 49
Study 9665109 — intervention group
Group type: COMPARATOR
Intervention: nonsupplemented, nonrandomly assigned group (n = 13)
Number of subjects: 49
Study 9665109 — intervention group
Group type: EXPERIMENTAL
Intervention: whole-protein-based and peptide-based formulas
Number of subjects: 49
Study 9665109 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline synthesis of fat (de novo hepatic lipogenesis)
Number of subjects: 49
Study 7666247 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 mumol isoflavones/kg body wt in soymilk
Number of subjects: 7
Study 7666247 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.9 mumol isoflavones/kg body wt in soymilk
Number of subjects: 7
Study 7666247 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.3 mumol isoflavones/kg body wt in soymilk
Number of subjects: 7
Study 7666247 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro anaerobic incubation of isoflavones with human feces
Number of subjects: 7
Study 7666247 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects excreting large amounts of fecal isoflavones
Number of subjects: 7
Study 2693995 — intervention group
Group type: EXPERIMENTAL
Intervention: l-tryptophan
Number of subjects: 34
Study 2693995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 34
Study 361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride
Number of subjects: 30
Study 361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 30
Study 361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin with polythiazide
Number of subjects: 30
Study 361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine with chlorthalidone
Number of subjects: 30
Study 361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin and clonidine
Number of subjects: 30
Study 361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin and diuretics
Number of subjects: 30
Study 361988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and diuretics
Number of subjects: 30
Study 30644982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled donor FMT (n=38)
Number of subjects: 73
Study 30644982 — intervention group
Group type: COMPARATOR
Intervention: Autologous FMT (n=35)
Number of subjects: 73
Study 28608013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (6 mmHg)
Number of subjects: 64
Study 28608013 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12 mmHg)
Number of subjects: 64
Study 28608013 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 64
Study 24647318 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nonclipped harvesting technique
Number of subjects: 40
Study 24647318 — intervention group
Group type: COMPARATOR
Intervention: Traditional clipped harvesting technique
Number of subjects: 40
Study 23641803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal intervention including a computerized patient activation tool, a web-based COPD guideline tool, and a COPD patient education toolkit.
Number of subjects: 30
Study 23641803 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation tool 'MyLungAge'.
Number of subjects: 30
Study 21377168 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognitive Skills Training (SCST)
Number of subjects: 68
Study 21377168 — intervention group
Group type: COMPARATOR
Intervention: Computerized neurocognitive remediation
Number of subjects: 68
Study 21377168 — intervention group
Group type: COMPARATOR
Intervention: Standard illness management skills training
Number of subjects: 68
Study 21377168 — intervention group
Group type: COMPARATOR
Intervention: Hybrid treatment (SCST and neurocognitive remediation)
Number of subjects: 68
Study 19646443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg) administered every 28 days for 24 weeks
Number of subjects: 54
Study 19646443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 17874925 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered intervention to reduce disruptive behavior
Number of subjects: 120
Study 15359673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bent-handle pliers
Number of subjects: 16
Study 15359673 — intervention group
Group type: COMPARATOR
Intervention: Straight-handle pliers
Number of subjects: 16
Study 11318525 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of IFN‐beta twice daily for four weeks (group A)
Number of subjects: 60
Study 11318525 — intervention group
Group type: COMPARATOR
Intervention: 6 MU once a day for four weeks (group B)
Number of subjects: 60
Study 9007770 — intervention group
Group type: EXPERIMENTAL
Intervention: Short CPM duration (3-5 hours per day) with CPM ROM increased 5 degrees twice daily
Number of subjects: 45
Study 9007770 — intervention group
Group type: EXPERIMENTAL
Intervention: Short CPM duration with CPM ROM increased daily to patient tolerance
Number of subjects: 45
Study 9007770 — intervention group
Group type: EXPERIMENTAL
Intervention: Long CPM duration (10-12 hours per day) with CPM ROM increased 5 degrees twice daily
Number of subjects: 45
Study 9007770 — intervention group
Group type: EXPERIMENTAL
Intervention: Long CPM duration with CPM ROM increased daily to patient tolerance
Number of subjects: 45
Study 9007770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CPM groups (short and long durations)
Number of subjects: 45
Study 9007770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-preferred CPM duration
Number of subjects: 45
Study 9007770 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-preferred CPM incremental increase in ROM
Number of subjects: 45
Study 9007770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 8110435 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.5 g/day) for 8 weeks
Number of subjects: 46
Study 8110435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2944688 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) during water immersion
Number of subjects: 0
Study 2944688 — intervention group
Group type: COMPARATOR
Intervention: Control experiments (no water immersion)
Number of subjects: 0
Study 29490466 — intervention group
Group type: EXPERIMENTAL
Intervention: Function and Behavior Focused Care intervention
Number of subjects: 336
Study 29490466 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonfallers)
Number of subjects: 336
Study 27678295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil (1.0×10^7 cells/intradermal injection/month for 4 to 12 doses)
Number of subjects: 42
Study 27678295 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 42
Study 24101716 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism MEAL Plan (behaviorally based parent-training curriculum)
Number of subjects: 10
Study 24101716 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 9)
Number of subjects: 10
Study 24294576 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove finger packs (Group A)
Number of subjects: 80
Study 24294576 — intervention group
Group type: COMPARATOR
Intervention: Septal clips (Group B)
Number of subjects: 80
Study 19940012 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with FOLFOX plus 5 mg/kg bevacizumab
Number of subjects: 30
Study 19940012 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with FOLFOX plus 2 mg/kg bevacizumab
Number of subjects: 30
Study 19940012 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with FOLFIRI
Number of subjects: 30
Study 19940012 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily) with FOLFOX
Number of subjects: 30
Study 19940012 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 30
Study 18981327 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 to 32 mg)
Number of subjects: 26
Study 18981327 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 to 50 mg)
Number of subjects: 26
Study 18981327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12166578 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen therapy (COT) > or = 15 h daily
Number of subjects: 246
Study 12166578 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontinuous oxygen therapy (NCOT) <15 h daily
Number of subjects: 246
Study 10622084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 50 IU
Number of subjects: 107
Study 10622084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 100 IU
Number of subjects: 107
Study 10622084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 8075589 — intervention group
Group type: EXPERIMENTAL
Intervention: Purged Autologous Bone Marrow Transplantation (ABMT)
Number of subjects: 95
Study 8075589 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 95
Study 2587289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (EX)
Number of subjects: 45
Study 2587289 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic stretching and flexibility exercises (PL)
Number of subjects: 45
Study 2587289 — intervention group
Group type: COMPARATOR
Intervention: Normal activities (CO)
Number of subjects: 45